Clinical trial registry changes: September 2026

Among the trials TrialRedline tracks, 67 changed their ClinicalTrials.gov record in September 2026: 3 status changes to terminated, withdrawn or suspended, 16 primary outcome text edits, 20 completion dates moved later, 1 completion date moved earlier, 20 enrollment changes, 29 other status changes. Each entry shows the previous and updated value and links to the registry's own version comparison.

67Trials with a recorded change
68Registry updates
57Sponsors

Trials terminated, withdrawn or suspended

3 in September 2026. Recruitment status changed to Terminated, Withdrawn or Suspended. Terminated first, then newest.

Primary outcome text edits

16 in September 2026. The text of the main study measures changed. Edits to capitalization, punctuation or spacing alone are left out. Newest first.

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: Posology: Proportion of participants free from Pericarditis Recurrence by Week 16 Time frame: From first administration of study drug up to Week 16 Measure: Long-Term Extension: Annualized rate of Pericarditis Recurrence through the end of the LTE. Time frame: Up to 24 Months. After: Measure: Posology: Proportion of participants free from Pericarditis Recurrence by Week 16 Time frame: From baseline up to Week 16 Measure: Long-Term Extension: Annualized rate of Pericarditis Recurrence through the end of the LTE. Time frame: Up to 24 Months.

Check registry source

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: Mortality rate at Day 28 from IP administration. Description: For the current study, the primary efficacy outcome measure will be the mortality rate from IP administration. Mortality is the most clinically relevant therapeutic endpoint for this population that is on IMV. The primary endpoint will be assessed at 28-days after treatment initiation. Time frame: 28 days. After: Measure: Mortality rate at Day 28 from IP administration. (Phase 2 and 3) Description: For the current study, the primary efficacy outcome measure will be the mortality rate from IP administration. Mortality is the most clinically relevant therapeutic endpoint for this population that is on IMV. The primary endpoint will be assessed at 28-days after treatment initiation. Time frame: 28 days.

Check registry source

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: The change from baseline at Week 12 in ocular pain assessed by VAS score. Description: Evaluate the efficacy and safety of urcosimod 0.05% as compared to placebo instilled 4 times/day in participants who have a documented ocular history of symptoms of neuropathic corneal pain. Time frame: From baseline (time of randomization) compared to Week 12.. After: Measure: The change from baseline at Week 12 in ocular pain assessed by Visual Analogue Scale (0-10) score. (Score of 10 is "worst possible pain".) Description: Evaluate the efficacy and safety of urcosimod 0.05% as compared to placebo instilled 4 times/day in participants who have a documented ocular history of symptoms of neuropathic corneal pain. Time frame: From baseline (time of randomization) compared to Week 12..

Check registry source

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: To assess the efficacy of TYRA-300 in LG IR-NMIBC participants Description: Complete response (CR) rate Time frame: at 3 months. After: Measure: To assess the efficacy of TYRA-300 in LG IR-NMIBC participants Description: Complete response (CR) rate at 3 months Time frame: at 3 months.

Check registry source

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: Complete response rate (CRR) Description: CRR is defined as the proportion of patients who achieved CR at the 3-month Visit. Time frame: 3 months. After: Measure: Complete Response Rate (CRR) Description: CRR is defined as the proportion of patients who achieved a complete response (CR) at the 3-month Visit. A patient was considered a CR if there was no detectable disease in the bladder based on visual observation (white light cystoscopy), biopsy of remaining lesions (if applicable), and voiding urine cytology. Time frame: 3 months.

Check registry source

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: Proportion of patients achieving ACR20 at Week 12 Time frame: Baseline to Week 12. After: Measure: Percentage of Participants Achieving ACR20 at Week 12 Description: Participants achieving American College of Rheumatology (ACR) 20 (responders) were defined as having ≥20% improvement in both the number of swollen and tender joints (66/68 joint counts) and ≥20% improvement in ≥3 of the following 5 measures: Patient's Global Assessment of Disease Activity (VAS), Patient's Assessment of Arthritis Pain (VAS), Health Assessment Questionnaire-Disability Index (HAQ-DI), Physician's Global Assessment of Disease Activity (VAS), and acute phase reactant as measured by hsCRP. Model-based estimates and 95% confidence intervals (CIs) were produced. Time frame: Week 12.

Check registry source

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: Cohort 1 and 2: Objective Response Rate Description: To evaluate the efficacy of LN-145 in participants with recurrent, metastatic, or persistent cervical carcinoma based on the objective response rate (ORR) as assessed by the Investigator per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 Time frame: Up to 60 months Measure: Cohort 3: Adverse Events Description: To characterize the safety profile of LN-145 in combination with pembrolizumab in participants with recurrent, metastatic, or persistent cervical carcinoma as assessed by incidence of adverse events. Time frame: Up to 60 months Measure: Cohort 4: Adverse Events Description: To explore the safety profile of LN-145 in previously enrolled participants with recurrent, metastatic, or persistent cervical carcinoma as assessed by incidence of adverse events. Time frame: Up to 60 months Measure: Cohort 4: Efficacy/Objective Response Rate Description: To explore the efficacy of LN-145 in previously enrolled participants with recurrent, metastatic, or persistent cervical carcinoma based on the objective response rate (ORR). Time frame: Up to 60 months Measure: Cohort 5: Adverse Events Description: To explore the safety profile of LN-145 in re-treated participants with recurrent, metastatic, or persistent cervical carcinoma as assessed by incidence of adverse events. Time frame: Up to 60 months Measure: Cohort 5: Efficacy/Objective Response Rate Description: To explore the efficacy of LN-145 in re-treated participants with recurrent, metastatic, or persistent cervical carcinoma based on the objective response rate (ORR). Time frame: Up to 60 months. After: Measure: Cohort 1 and 2: Objective Response Rate Description: To evaluate the efficacy of LN-145 in participants with recurrent, metastatic, or persistent cervical carcinoma based on the objective response rate (ORR) as assessed by the Investigator per Response Evaluation Criteria In Solid Tumors (RECIST v1.1) for target lesions based on imaging: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR. Time frame: Up to 60 months Measure: Cohort 3: Number of Participants With Adverse Events Description: To characterize the safety profile of LN-145 in combination with pembrolizumab in participants with recurrent, metastatic, or persistent cervical carcinoma as assessed by number of participants with adverse events. Time frame: Up to 60 months Measure: Cohort 4: Number of Participants With Adverse Events Description: To explore the safety profile of LN-145 in previously enrolled participants with recurrent, metastatic, or persistent cervical carcinoma as assessed by number of participants with adverse events. Time frame: Up to 60 months Measure: Cohort 4: Efficacy/Objective Response Rate Description: To explore the efficacy of LN-145 in previously enrolled participants with recurrent, metastatic, or persistent cervical carcinoma based on the objective response rate (ORR) as assessed by the Investigator per Response Evaluation Criteria In Solid Tumors (RECIST v1.1) for target lesions based on imaging: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR. Time frame: Up to 60 months Measure: Cohort 5: Number of Participants With Adverse Events Description: To explore the safety profile of LN-145 in re-treated participants with recurrent, metastatic, or persistent cervical carcinoma as assessed by number of participants with adverse events. Time frame: Up to 60 months Measure: Cohort 5: Efficacy/Objective Response Rate Description: To explore the efficacy of LN-145 in re-treated participants with recurrent, metastatic, or persistent cervical carcinoma based on the objective response rate (ORR) as assessed by the Investigator per Response Evaluation Criteria In Solid Tumors (RECIST v1.1) for target lesions based on imaging: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR. Time frame: Up to 60 months.

Check registry source

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: Treatment emergent adverse events. After: Measure: Treatment emergent adverse events Measure: SAT-3247 effect on fat fraction in biceps brachii.

Check registry source

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: Number of adverse events in those treated with sevasemten or placebo Measure: Severity of adverse events in those treated with sevasemten or placebo Measure: Change from Baseline in serum Creatine Kinase Measure: Change from Baseline in the North Star Ambulatory Assessment scale. After: Measure: Number of treatment emergent adverse events in those treated with sevasemten or placebo Measure: Severity of treatment emergent adverse events in those treated with sevasemten or placebo Measure: Change from Baseline in serum Creatine Kinase Measure: Change from Baseline in total North Star Ambulatory Assessment score.

Check registry source

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: Determine the effect of ARS-2 (0.5 mg or 1 mg) versus placebo on itch and hive. After: Measure: Determine the effect of ARS-2 (0.5 mg or 1 mg) versus placebo on itch.

Check registry source

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: Response Rate of participants achieving at least a 50% improvement in the American College of Rheumatology criteria (ACR50). After: Measure: Percentage of Participants Achieving an American College of Rheumatology 50% (ACR50) Response at Week 12.

Check registry source

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: Percent change from baseline in cerebrospinal fluid (CSF) heparan sulfate (HS) concentration (Cohort A) Measure: Change from baseline in the Vineland Adaptive Behavior Scale, Third Edition (Vineland-3)(Cohort A). After: Measure: Ratio to baseline in cerebrospinal fluid (CSF) heparan sulfate (HS) concentration (Cohort A) Measure: Change from baseline in the Vineland Adaptive Behavior Scale, Third Edition (Vineland-3)(Cohort A).

Check registry source

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: Hidradenitis Suppurativa Clinical Response 75. After: Measure: Percentage of Participants Achieving Hidradenitis Suppurativa Clinical Response (HiSCR) 75 at Week 12.

Check registry source

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: Change in Investigator Global Assessment (IGA) at Week 8. After: Measure: vIGA-AD Success at Week 4 Measure: EASI-75 at Week 4 Measure: EASI-90 at Week 8 Measure: EASI-100 at Week 8.

Check registry source

Completion dates moved later

20 in September 2026. Primary completion date moved later while its type (estimated or actual) stayed the same. Largest move first.

Completion dates moved earlier

1 in September 2026. Primary completion date moved earlier while its type stayed the same. Largest move first.

Enrollment changes

20 in September 2026. The participant count changed. Planned and actual counts are shown as recorded. Newest first.

Other recruitment status changes

29 in September 2026. Any other change of recruitment status, such as recruiting to completed. Newest first.

Showing 25 of 29. Browse all tracked trials to open the rest.

Cite this report

TrialRedline, “Clinical trial registry changes: September 2026”. https://trialredline.com/reports/2026-09

Based on public ClinicalTrials.gov record history. How we collect and check the data